ESR1 and breast carcinoma: Breast cancer is a leading cause of death in women worldwide.[1] In Western countries, approximately 60% to 80% of breast cancer patients are positive for estrogen receptor (ER) overexpression, progesterone receptor (PR) overexpression, or both.[2] In this patients population, existing studies have demonstrated that endocrine therapy (ET) has a positive impact on survival.